Anti-nucleolin agent-conjugated nanoparticles

Abstract

A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.

1 . A composition, comprising an anti-nucleolin agent conjugated to nanoparticles,
 wherein the nanoparticles are non-magnetic, not iron oxide and not polyacrylamide.   
     
     
         2 . The composition of  claim 1 , wherein the nanoparticles comprise at least one member selected from the group consisting of metals, elements and oxides. 
     
     
         3 . The composition of  claim 1 , wherein the nanoparticles comprise gold. 
     
     
         4 . The composition of  claim 1 , wherein the anti-nucleolin agent comprises at least one member selected from the group consisting of an anti-nucleolin oligonucleotide, an antibody, a nucleolin targeting protein and a GRO. 
     
     
         5 - 8 . (canceled) 
     
     
         9 . The composition of  claim 1 , further comprising a cyanine dye. 
     
     
         10 . (canceled) 
     
     
         11 . The composition of  claim 1 , wherein the nanoparticles have an average diameter of 1 to 20 nm. 
     
     
         12 . The composition of  claim 1 , wherein the nanoparticles comprise at least one member selected from the group consisting of gold, platinum, iridium and palladium. 
     
     
         13 . (canceled) 
     
     
         14 . A pharmaceutical composition for treating cancer, comprising
 a composition, comprising an anti-nucleolin agent conjugated to nanoparticles, and   a pharmaceutically acceptable carrier.   
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the nanoparticles comprise at least one member selected from the group consisting of metals, elements and oxides. 
     
     
         16 . (canceled) 
     
     
         17 . The pharmaceutical composition of  claim 14 , wherein the anti-nucleolin agent comprises at least one member selected from the group consisting of an anti-nucleolin oligonucleotide, an antibody, a nucleolin targeting protein and a GRO. 
     
     
         18 - 21 . (canceled) 
     
     
         22 . The pharmaceutical composition of  claim 14 , wherein the anti-nucleolin agent comprises AS1411. 
     
     
         23 . The pharmaceutical composition of  claim 14 , further comprising a cyanine dye. 
     
     
         24 . The pharmaceutical composition of  claim 14 , wherein the nanoparticles have an average diameter of 1 to 50 nm. 
     
     
         25 . (canceled) 
     
     
         26 . The pharmaceutical composition of  claim 14 , wherein the nanoparticles comprise at least one member selected from the group consisting of gold, platinum, iridium and palladium. 
     
     
         27 . A method of treating cancer, comprising administering an effective amount of the pharmaceutical composition of  claim 14 , to a patient in need thereof. 
     
     
         28 . The method of treating cancer of  claim 27 , wherein the cancer is selected from the group consisting of melanoma, lymphoma, plasmocytoma, sarcoma, glioma, thymoma, leukemia, breast cancer, prostate cancer, colon cancer, liver cancer, esophageal cancer, brain cancer, lung cancer, ovary cancer, cervical cancer and hepatoma. 
     
     
         29 . (canceled) 
     
     
         30 . The method of treating cancer of  claim 27 , further comprising administering a second cancer treatment selected from the group consisting of vinorelbine, mytomycin, camptothecin, cyclyphosphamide, methotrexate, tamoxifen citrate, 5-fluorouracil, irinotecan, doxorubicin, flutamide, paclitaxel, docetaxel, vinblastine, imatinib mesylate, anthracycline, letrozole, arsenic trioxide, anastrozole, triptorelin pamoate, ozogamicin, irinotecan hydrochloride, BCG live, leuprolide acetate implant, bexarotene, exemestane, topotecan hydrochloride, gemcitabine HCL, daunorubicin hydrochloride, toremifene citrate, carboplatin, cisplatin, oxaliplatin and any other platinum-containing oncology drug, trastuzumab, lapatinib, gefitinb, cetuximab, panitumumab, temsirolimus, everolimus, vandetanib, vemurafenib, crizotinib, vorinostat, bevacizumab, radiation therapy, hyperthermia, gene therapy and photodynamic therapy. 
     
     
         31 - 33 . (canceled) 
     
     
         34 . An agent for imaging, comprising the composition of  claim 1 , and a pharmaceutically acceptable carrier,
 wherein the nanoparticles are non-magnetic, not iron oxide and not polyacrylamide.   
     
     
         35 . A method of imaging cancer in vivo, comprising:
 administering the imaging agent of  claim 34 , to a subject and   forming an image of the imaging agent present in the subject.   
     
     
         36 . An imaging agent for imaging cancer in vivo, comprising the composition for treating cancer of  claim 14 , further comprising a cyanine dye,
 wherein the nanoparticles are non-magnetic, not iron oxide and not polyacrylamide.